Pembrolizumab
Phase 2Active 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Fallopian Tube Carcinoma
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Trial Timeline
Mar 6, 2019 → Mar 6, 2025
NCT ID
NCT03732950About Pembrolizumab
Pembrolizumab is a phase 2 stage product being developed by Merck for Recurrent Fallopian Tube Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT03732950. Target conditions include Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma.
What happened to similar drugs?
6 of 20 similar drugs in Recurrent Fallopian Tube Carcinoma were approved
Approved (6) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02083484 | Pre-clinical | Completed |
| NCT07302347 | Phase 1/2 | Recruiting |
| NCT07089992 | Phase 2 | Recruiting |
| NCT07007273 | Phase 2 | Recruiting |
| NCT04569461 | Phase 2 | Withdrawn |
| NCT05815927 | Phase 3 | Recruiting |
| NCT05852223 | Phase 2 | Recruiting |
| NCT05879120 | Phase 2 | Withdrawn |
| NCT06004336 | Phase 2 | Recruiting |
| NCT05496036 | Phase 2 | Recruiting |
| NCT05131919 | Phase 2 | Active |
| NCT05197322 | Phase 2 | Recruiting |
| NCT05406713 | Phase 2 | Active |
| NCT05025813 | Phase 2 | Recruiting |
| NCT06413095 | Phase 1 | Completed |
| NCT05191472 | Phase 2 | Terminated |
| NCT05204160 | Phase 2 | Withdrawn |
| NCT04575961 | Phase 2 | Active |
| NCT04417166 | Phase 2 | Recruiting |
| NCT05188508 | Phase 2 | Recruiting |
Competing Products
20 competing products in Recurrent Fallopian Tube Carcinoma